Dalvance

(Dalbavancin)

Dalvance

Drug updated on 11/10/2023

Dosage FormInjection (intravenous: 500mg)
Drug ClassLipoglycopeptide antibacterials
Ongoing and Completed StudiesClinicalTrials.gov

Indication

  • For the treatment of adult and pediatric patients with acute bacterial skin and skin structure infections (ABSSSI) caused by designated susceptible strains of Gram-positive microorganisms